Alternatively spliced isoform in cancer and methods of use thereof
AssigneeThe Children's Hospital of Philadelphia
InventorsAndrei THOMAS-TIKHONENKO, Manuel TORES-DIZ
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of predicting resistance to a purine analog by detecting the presence of a NT5ex4a isoform. Further provided herein are methods of treating the subject with resistance by administering a purine biosynthesis inhibitor.
Claims23
A method of predicting resistance of a cancer patient to a purine analog comprising assaying a cancer cell isolated from the patient to determine the presence of alternatively spliced isoform NT5ex4a of the NT5C2 gene.
-64. (canceled)
A method of treating a patient with cancer comprising administering an effective amount of a purine biosynthesis inhibitor to said patient, wherein the subject is determined to have a cancer with a NT5ex4a isoform.
(canceled)
A method of treating a patient with a gastrointestinal disease comprising administering an effective amount of a purine biosynthesis inhibitor to said patient, wherein the subject is determined to have a NT5ex4a isoform.
-87. (canceled)
Dependencies are inferred from the claim text.